Gem-difluorinated C-glycoside compounds as anti-cancer agents
Patent number: 10272065
Abstract: The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podophyllotoxin gem-difluorinated C-glycoconjugated derivatives display improved conformational and chemical stability, and improved cytotoxicity exhibited against drug-resistant cancer cell lines.
Type: Grant
Filed: January 13, 2014
Date of Patent: April 30, 2019
Assignee: Benoit & Côté
Inventor: Steve N. Slilaty
GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS
Publication number: 20150353573
Abstract: The present document describes a synthesis of a class of gem-difluorinated C-glycoside compounds derived from podophyllotoxin, which may be used, but not exclusively, in oncology for the treatment of cancer. More particularly, the podophyllotoxin gem-difluorinated C-glycoconjugated derivatives display improved conformational and chemical stability, and improved cytotoxicity exhibited against drug-resistant cancer cell lines.
Type: Application
Filed: January 13, 2014
Publication date: December 10, 2015
Applicant: ADVANOMICS CORPORATION
Inventor: Steve N. SLILATY
Method for making an improved cloning vector containing marker inactivation system
Patent number: 6500619
Abstract: Provided are lacZ&agr; gene fragments which have been modified to introduce multiple restriction enzyme sites. Vectors according to the present invention include at least one promoter operatively linked to a DNA sequence encoding lacZ&agr;(&agr;-peptide); multiple cloning sites cleavable by distinct restriction enzymes which have been introduced within a lacZ coding sequence from and including the codon for amino acid 8, and in the lacZ coding sequence downstream of the codon for amino acid 8, in forming the modified lacZ&agr; coding sequence; and a replicon. Also provided are methods of using the vectors wherein a DNA molecule is cloned into at least one restriction enzyme site in the modified lacZ&agr; coding sequence, in forming recombinant vectors; introducing the recombinant vectors into competent host cells; growing the host cells in the presence of a chromogenic substrate cleavable by &bgr;-galactosidase; and screening for indicia of lac operon marker inactivation.
Type: Grant
Filed: September 19, 2000
Date of Patent: December 31, 2002
Assignee: Genomics One Corporation
Inventors: Steve N. Slilaty, Suzanne Lebel
Cloning vector containing marker inactivation system
Patent number: 6127171
Abstract: Provided are lacZ.alpha. gene fragments which have been modified to introduce multiple restriction enzyme sites. Vectors according to the present invention include at least one promoter operatively linked to a DNA sequence encoding lacZ.alpha. (.alpha.-peptide); multiple cloning sites cleavable by distinct restriction enzymes which have been introduced within a lacZ coding sequence from and including the codon for amino acid 8, and in the lacZ coding sequence downstream of the codon for amino acid 8, in forming the modified lacZ.alpha. coding sequence; and a replicon. The vector may further comprise one or more additional features useful for protein expression and other molecular manipulations. Also provided are methods of using the vectors wherein a DNA molecule is cloned into at least one restriction enzyme site in the modified lacZ.alpha.
Type: Grant
Filed: May 1, 1998
Date of Patent: October 3, 2000
Assignee: Genomics One Corporation
Inventors: Steve N. Slilaty, Suzanne Lebel
Lytic .beta.-1,3-glucanase gene
Patent number: 5883244
Abstract: The present invention relates to recombinant .beta.-1,3-glucanase essentially free of proteases. The enzyme is obtained through the use of a recombinant DNA expression vector which comprises a DNA sequence encoding the .beta.-1,3-glucanase gene or mutants and variants thereof placed under the control of an exogenous expression promoter, preferably a bacterial promoter. Also, the .beta.-1,3-glucanase gene may include sequences flanking the open reading frame of the native .beta.-1,3-glucanase gene. The present invention also relates to a microorganism transformed with a recombinant DNA expression vector comprising the .beta.-1,3-glucanase gene or mutants and variants thereof under the control of an exogenous expression promoter.
Type: Grant
Filed: June 29, 1993
Date of Patent: March 16, 1999
Assignee: Her Majesty the Queen in right of Canada, as represented by the National Research Council of Canada
Inventors: Shi-Hsiang Shen, Pierre Chretien, Lison Bastien, Steve N. Slilaty
Process for conducting site-directed mutagenesis
Patent number: 5071743
Abstract: The present invention relates to an approach for conducting site-directed mutagenesis using double-stranded DNA templates. The approach involves the development of a method for generating structures capable of directing full-length complementary-strand synthesis from double-stranded plasmid DNA. These structures are formed following heat denaturation and cooling of linearized plasmid DNA molecules in the presence of what is referred to as a "closing oligonucleotide". A "closing oligonucleotide" is a single-stranded oligonucleotide consisting of a sequence complementary to either or both free ends of one of the two plasmid DNA strands. The "closing oligonucleotide" therefore functions as an agent for recircularization of a DNA strand and generation of a primer-circular template structure suitable for polymerase-dependent full-length complementary-strand synthesis and ligation into a covalently-closed heteroduplex DNA molecule.
Type: Grant
Filed: October 27, 1989
Date of Patent: December 10, 1991
Assignee: Her Majesty the Queen in right of Canada, as represented by the National Research Council of Canada
Inventors: Steve N. Slilaty, Shi-hsiang Shen, Susan Lebel
AI
